138 related articles for article (PubMed ID: 11562394)
1. Irinotecan-induced dysarthria.
Baz DV; Bofill JS; Nogueira JA
J Natl Cancer Inst; 2001 Sep; 93(18):1419-20. PubMed ID: 11562394
[No Abstract] [Full Text] [Related]
2. Irinotecan chemotherapy associated with transient dysarthria and aphasia.
De Marco S; Squilloni E; Vigna L; Bertagnolio MF; Sternberg CN
Ann Oncol; 2004 Jul; 15(7):1147-8. PubMed ID: 15205214
[No Abstract] [Full Text] [Related]
3. [Dysarthria during irinotecan administration].
Ceccaldi B; Kara F; Mommeja-Marin H; Bègue M; Saint Blancard P; Le Marec E; Hauteville D
Rev Med Interne; 2002 Nov; 23(11):950-1. PubMed ID: 12481397
[No Abstract] [Full Text] [Related]
4. [A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].
Sogabe S; Yuki S; Takano H; Kobayashi Y; Nakatsumi H; Sasaki T; Kawamoto Y; Fukushima H; Iwanaga I; Uehata Y; Komatsu Y; Asaka M
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1375-7. PubMed ID: 21829085
[TBL] [Abstract][Full Text] [Related]
5. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
Dodds HM; Bishop JF; Rivory LP
J Natl Cancer Inst; 1999 Jan; 91(1):91-2. PubMed ID: 9890180
[No Abstract] [Full Text] [Related]
6. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
7. A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
Joseph R; Dasanu CA
J Oncol Pharm Pract; 2014 Oct; 20(5):393-6. PubMed ID: 24103898
[TBL] [Abstract][Full Text] [Related]
8. Dysarthria induced by irinotecan in a patient with colorectal cancer.
Lee KA; Kang HW; Ahn JH; Suk HJ; Kim H
Am J Health Syst Pharm; 2013 Jul; 70(13):1140-3. PubMed ID: 23784161
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Hamberg P; De Jong FA; Brandsma D; Verweij J; Sleijfer S
Acta Oncol; 2008; 47(5):974-8. PubMed ID: 17924208
[No Abstract] [Full Text] [Related]
10. Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting.
Sears S; McNally P; Bachinski MS; Avery R
Gastrointest Endosc; 1999 Dec; 50(6):841-4. PubMed ID: 10570349
[No Abstract] [Full Text] [Related]
11. Central nervous system toxicity induced by irinotecan.
Hamberg P; Donders RC; ten Bokkel Huinink D
J Natl Cancer Inst; 2006 Feb; 98(3):219. PubMed ID: 16449682
[No Abstract] [Full Text] [Related]
12. [A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
Sogabe S; Yuki S; Takagi T; Miyazaki T; Takano H; Kawamoto Y; Nakatsumi H; Sasaki T; Iwanaga I; Uehata Y; Asaka M; Komatsu Y
Gan To Kagaku Ryoho; 2010 Mar; 37(3):535-8. PubMed ID: 20332699
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan-induced immune thrombocytopenia.
Bozec L; Bierling P; Fromont P; Lévi F; Debat P; Cvitkovic E; Misset JL
Ann Oncol; 1998 Apr; 9(4):453-5. PubMed ID: 9636839
[TBL] [Abstract][Full Text] [Related]
14. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
15. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Fernandez FG; Ritter J; Goodwin JW; Linehan DC; Hawkins WG; Strasberg SM
J Am Coll Surg; 2005 Jun; 200(6):845-53. PubMed ID: 15922194
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Comella P; Lorusso V; Maiorino L; Casaretti R; Cannone M; Massidda B; Putzu C; Leo S; Roselli M; Mancarella S; Palmeri S; Greco E; Vessia G; Sandomenico C; Franco L
Cancer Chemother Pharmacol; 2009 Oct; 64(5):893-9. PubMed ID: 19189106
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
Pazdur R
J Gastroenterol; 2000; 35 Suppl 12():131. PubMed ID: 10779234
[No Abstract] [Full Text] [Related]
18. [Clinical activity spectrum of irinotecan].
Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
[TBL] [Abstract][Full Text] [Related]
19. Phlebitis due to irinotecan.
Tas F; Karagol H; Karadeniz A; Topuz E
Clin Oncol (R Coll Radiol); 2003 May; 15(3):167. PubMed ID: 12801060
[No Abstract] [Full Text] [Related]
20. Patient with angina secondary to capecitabine.
Maciá-Escalante S; Guillén-Ponce C; Molina-Garrido MJ; Carrato-Mena A
Clin Transl Oncol; 2005 Aug; 7(7):335. PubMed ID: 16185598
[No Abstract] [Full Text] [Related]
[Next] [New Search]
